NSI-189
From PeptideSciences101, the open peptide reference. · Last updated: October 7, 2025
This article is a stub. A peer-reviewed deep-dive is in preparation. Help contribute to expand it.
…
Overview
Experimental neurogenic compound that stimulates hippocampal neurogenesis.
Reported benefits
Hippocampal growth, potential depression treatment, cognitive enhancement
Protocols & dosing
Typical dosage: Research protocols vary (research).
Detailed dosing protocols have not yet been catalogued.
FDA & legal status
NSI-189 is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.
| Country | Status |
|---|---|
| United States | Research use only |
| United Kingdom | Prescription-only / not licensed |
| Canada | Prescription-only / Schedule F if licensed |
| Australia | TGA-scheduled |
Vendor information
PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.
Side effects & safety
Reported side effects: Experimental. Side effects under investigation
References
No external sources have been catalogued for this article yet.
Related peptides
- Cerebrolysin — Neuroprotection, recovery
- Cortexin — Neuropeptide complex
- Dihexa — Potent cognitive enhancer
- FGL (Fibroblast Growth Loop) — NCAM mimetic
- Memantine — NMDA antagonist
- NA-Semax-Amidate — Triple modified Semax
Categories: Cognitive Enhancement